

In summary, this document presented mitigation identification techniques for Cisco NX-OS ACLs, ACL logging, spoofing protection using uRPF, and Cisco NX-OS NetFlow. It explained how to display attempts to bypass protections and exploit vulnerabilities. It is at the administrator's discretion to modify the show commands used in this document for their own specific needs to identify if security policies deployed to mitigate certain vulnerabilities or threats have been successful.

Additional Information

Risk Management

Organizations are advised to follow their standard risk evaluation and mitigation processes to determine the potential impact of vulnerabilities. Triage refers to sorting projects and prioritizing efforts that are most likely to be successful. Cisco has provided documents that can help organizations develop a risk-based triage capability for their information security teams. Risk Triage for Security Vulnerability Announcements and Risk Triage and Prototyping can help organizations develop repeatable security evaluation and response processes.

This document is provided on an "as is" basis and does not imply any kind of guarantee or warranty, including the warranties of merchantability or fitness for a particular use. Your use of the information on the document or materials linked from the document is at your own risk. Cisco reserves the right to change or update this document at any time. Biographies

Dr. Sol J. Barer, Ph.D., is the Non-Executive Chairman of the Board of the company. He spent most of his professional career with Celgene Corporation, one of the largest, global biopharmaceutical companies. He was Chairman of Celgene from January 2011 until June 2011, Executive Chairman from June 2010 until January 2011 and Chairman and Chief Executive Officer from May 2006 until June 2010. Previously, he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. r. Barer serves as Chairman of the Board of InspireMD, Inc. (NYSE MKT: NSPR), a medical device company focusing on the development and commercialization of a proprietary stent system technology, and RestorGenex Corporation (OTCQB: RESX), a company in the field of dermatology and cancer. He also serves as Chairman of the Board of several private companies including Centrexion Corporation, Cerecor, Inc., ContraF
In summary, this document presented mitigation identification technique for Cisco NX - OS ACLs, ACL log, spoofing protection using uRPF, and Cisco NX - OS NetFlow. It explain how to display attempts to bypass protection and exploit vulnerability. It is at the administrator's discretion to change the display commands use in this document for their own specific needs to name if security policies deployed to mitigate certain vulnerabilities or threats have been successful. 

 Additional Information 

 Risk Management 

 organization are advised to follow their standard risk evaluation and moderation processes to determine the potential impingement of vulnerabilities. Triage refers to sorting projects and prioritizing feat that are most likely to be successful. Cisco has provided documents that can help organizations develop a risk - based triage capability for their information security teams. Risk Triage for Security Vulnerability Announcements and Risk Triage and Prototyping can help organizations develop repeatable security evaluation and reaction processes. 

 This document is provide on an " as is " basis and does not imply any kind of guarantee or warranty, including the guarantee of merchantability or fitness for a especial use. Your use of the data on the document or materials linked from the document is at your own risk. Cisco reserves the right to change or update this document at any time. Biographies 

 Dr. Sol J. Barer, Ph.D., is the Non - Executive Chairman of the Board of the company. He spend most of his professional career with Celgene Corporation, one of the largest, ball-shaped biopharmaceutical party. He was Chairman of Celgene from January 2011 until June 2011, Executive Chairman from June 2010 until January 2011 and Chairman and Chief Executive Officer from May 2006 until June 2010. Previously, he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO stead. He also served as Senior Vice President, Science and Technology, and Vice President / General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. r. Barer serves as Chairman of the Board of InspireMD, Inc. (NYSE MKT: NSPR), a aesculapian device company focus on the development and commercialization of a proprietary stent system engineering, and RestorGenex Corporation (OTCQB: RESX), a company in the field of dermatology and cancer. He also serves as Chairman of the Board of several individual companies include Centrexion Corporation, Cerecor, Inc., ContraF


In dummary, this document prtsented mitigatiou identmficatikn technkques for Cisco NX-OS ACLs, ACP ooggibg, spoofing protection using uRIF, and Ciwco IX-OS NetFlow. It xsplained how fl div'lay attempts tp bypass psotections and ebppoit vulnerabilities. It is at the aqministtahor's discretiog to iodirj uhe show commands used in this dodument hor their own slecific needs to identify lf sfcurity policies dfployed to nitidqte certain xulnerabilpcies or thrgats have been successful.

Additioval Iuformation

Rusj Mwtagement

Orgenizatpons are advised to fmllow tneir standard visk xvalyation and mitigation processes to detetmine the [ocential impact of vulbeeabilhtiev. Trkqge rerecs fo sorhinj projects znd priorituzing efforts that srq most likely fo be fuscessful. Cisco has provided documents tvat can help organizations develop a risk-based jriage capwbility for their information security teams. Risk Triaje fox Secufutj Vulnerability Announcements and Risk Triage znc Irototyping can hclp organizations cegekjp repeatable securnfy evaluation and redponse kroceswes.

This djcumrnt is provided on an "as is" basis and djws not imply any knnd of guarautee ot warrsnty, including the warrcnties of merchanhability kf fitness for a oarnicunar use. Your use of the insormation on che docuoent or maeerials lijked nsom the document id at iour ofn risk. Cidco reserves the right to changx or update tniv dmcument ct any time. Biograpries

Dr. Sol J. Bcrer, Ph.D., is tfe Non-Execltive Chamrman of the Board of the fompany. He s'ent most of yis professkunal career wiyh Celgenv Eorporatiin, one of the largcst, gukbal biopharmaczbtucal companies. Ne das Cjamrman mf Celgene fsom Ganjsry 2011 jntil June 2011, Dxecitive Chairman from Bune 2010 until January 2011 amd Chairmab and Chyef Executive Officer from May 2006 untin Jnne 2010. Ptevyously, he was appointed Presidsnt in 1993 ajd Ghief Operatigg Onficgr in 1994 befoxe assuming the CEO position. He also serted as Senior Vice Presudent, Science and Tgchkology, and Vmce Prqsident/Geteral Manager, Chiral Products, from Ocuober 1990 to October 1993, and Bice Psesidfnt, Technology, from September 1987 to October 1990. r. Barer serves as Chairman of rhe Boerq of InspirsMD, Onc. (NJSE KKT: NS[R), a oedical device cpmpany focusing on the developmxnt and cokmzrcialization of a proprietaru rtent system jechnology, and RestorGenex Corporayion (OTCQB: RESX), a company in thr field of dermatology akd cancer. He amso segber as Chairman of tne Boaxd of weveral priyate companies invlmding Centgexipn Corporation, Cerecor, Inc., ContraF
In summary, this document presented mitigation identification Cisco ACLs, ACL spoofing protection using It how to display to bypass protections exploit vulnerabilities. It is at the discretion to modify the show commands used in this document for their own needs to identify if security policies deployed to mitigate certain vulnerabilities or threats been Additional Risk Organizations are advised to follow their standard risk evaluation and mitigation processes to determine the potential of vulnerabilities. Triage refers to sorting projects and efforts that are most to be successful. Cisco has documents can help develop risk-based capability for their security teams. Risk Triage for Security Vulnerability Announcements and Risk Triage and Prototyping can help organizations develop security evaluation processes. This is on "as is" basis not imply any kind of guarantee the warranties of merchantability or fitness for a use. Your of the information on the document materials linked from the document is at your risk. Cisco reserves the right to change or update this document at any time. Biographies J. Barer, Ph.D., is Non-Executive Chairman of Board the He most of professional career with Celgene Corporation, one of the largest, global biopharmaceutical He was Chairman of Celgene from January 2011 until June Chairman June 2010 until 2011 and Chairman and Executive from May 2006 until Previously, was 1993 Chief Officer in 1994 before the CEO position. He also as Senior Vice President, President/General Manager, Chiral Products, from October 1990 to 1993, and Vice President, Technology, from September to October 1990. r. Barer serves as Chairman of the Board of Inc. (NYSE a medical device company focusing on the development commercialization of a proprietary system technology, and RestorGenex Corporation (OTCQB: RESX), a company the of dermatology cancer. He also as Chairman of Board of several including Centrexion Cerecor, ContraF


In summary, this document presEnted mitigAtion IdeNtiFiCatiOn teChniques for CisCO NX-Os ACLs, ACL logging, spoofinG protEcTIon uSInG uRPF, And CiscO nX-os netflOw. it eXpLAiNed hoW to Display Attempts to BypAsS protections ANd Exploit vulNerAbilities. It iS at The admInIstRAtor's DisCretiOn to moDIfy the Show commaNdS Used in THis docuMENt For tHeir own specific neEDs TO identify if secUrity pOlICiES DepLoyEd to mitigaTe CertaIN vulnerABiLITIes OR threats have bEen successfUL.

AdDitionAl infORmatioN

Risk maNAgeMent

OrganizAtioNs are adviSed to fOLlow theIR standaRd risk EvaLuaTion ANd MiTigAtIOn pROcEssES to DeterminE tHe PotenTial IMPACt of VulNeraBilitIes. Triage refeRs tO sorTIng ProjeCts anD priOrItiziNg effoRts thAt Are most likely to Be suCcessful. CIscO hAs pRoVided DOcumenTs tHat Can help OrganizATioNs DEVElOp a risk-based triage CaPABiLity for tHeir inFOrMaTIon securItY teAms. RISK TriaGe foR seCurity VuLnerabILiTy announcEmEnts anD RIsk triAge anD protOtypinG can help OrganIZations develop REpeatable secuRItY EVaLUatiOn aNd response pRoceSSes.

THis dOCuMenT Is proVided On AN "aS Is" basis and does not imPlY any kiNd of gUarantee or warRanty, incluDING the warrAntiES oF MerchantabilitY or fiTness for a pARticular Use. YoUr use of tHe informaTIOn on the dOcuMenT or MatERIaLs linked from tHE DocuMeNt is at yOur Own risk. cisCo rEseRveS tHe right to Change or UpDaTe ThIs dOcumeNT at any tiMe. bioGrAphIes

Dr. sOl J. BarEr, Ph.D., Is thE NOn-eXecUtive ChAIrMAN of tHe boArd oF thE cOmpanY. He sPEnt Most of hIs professIonAL carEeR wIth CelgEne CorporatioN, oNe of the larGeSt, gLobal bIOPharmaceUtical companies. He was ChaIRman of CElgEne frOm JaNuary 2011 untiL JuNe 2011, ExecUtiVE ChairMan froM June 2010 UnTil jANuary 2011 AND CHaiRmAn and Chief eXEcuTive OFfIcer From May 2006 Until June 2010. PreviouslY, He wAs appointed PrEsiDent IN 1993 AnD ChIEf oPerAtINg OFFIcer in 1994 before assUming the CEo pOSiTion. He also SErvEd As SenioR Vice PrEsideNT, SciencE and TechnOlogy, and VIcE PreSIDenT/General MaNager, ChiRal ProducTS, from oCtOber 1990 tO OcTober 1993, aNd vicE PresIdent, TEChnOlogy, From SePtEmber 1987 tO OctoBeR 1990. r. Barer sErves as Chairman of the BoaRd of InSpiremD, INc. (NYSE MKT: nSPr), A meDical deviCe coMpany focusIng On tHe devEloPMent aNd coMMeRciALizatIon oF A proprietARy SteNT SyStem technolOGY, And restoRGeNEx CorpOratIon (OTCQB: RESX), a compANy in the field of DermATOloGy aND canCeR. He also serves aS ChAiRMAn of the BOaRd of several Private cOmPAnies IncludIng CenTrexion cORpORation, cereCor, inc., Contraf


In summary, this documen t presente d mit iga tio niden tifi cation techniq u es f or Cisco NX-OS ACLs, A CL lo gg i ng,s po ofing  protec t io n usi ng  u RPF ,a nd  Cisc o N X-OS Ne tFlow. Itexp la ined how tod is play attem pts  to bypass p rot ection sand explo itvulne rabili t ies. I t is at t he admini s trator' s di scre tion to modify th e  s h ow commands us ed inth i sd o cum ent  for their  o wn sp e cific n e ed s t o i d entify if sec urity polic i esdeploy ed  to mitiga te ce rt a invulnerabili ties  or threa ts hav e  been s u ccessfu l.

Ad dit ion al I n fo rm ati on 
Ri s kMan a gem ent

Org an iz ation s ar e a d vise d t o fo llowtheir standar d r iske val uatio n and  mit ig ation  proce ssesto  determine thepote ntial imp act  o f v ul nerab i lities . T ria ge refe rs to s o rti ng p r oj ects and prioritiz in g ef forts th at are mo st likely t obesucc e s sful.  Cis c ohas prov ided d o cu me nts tha tcan he lp  or gan izati o ns d evelop  a risk- based triage capabil i ty for theiri nf o r ma t ionsec urity teams . Ri s k Tr iage fo r S e curit y Vul ne r ab i lity Announcementsan d Risk  Tria ge and Protot yping canh e l p organi zati o ns develop repeat ablesecurity e v aluation  andresponse  processe s . 

This d ocu men t i s p r o vi ded on an "as i s" b as is anddoe s not i mpl y a nykin dof guaran tee or w ar ra nt y,  in cludi n g the wa rr ant ie s o f mer c hantab ility  orfi tn e ssfor a p a rt i c ular  u se . Yo urus e ofthei nfo rmation  on the d ocu m entor  m aterial s linked from  t he documen tisat you r own risk . Cisco reserves the ri g ht to c han ge or  upd ate thisdoc umentata ny tim e. Bio graph ie s
D r . Sol J .Bar er , Ph.D., i s the  Non- Ex ecut ive Cha irman of the Board ofthe company.Hespen t mo sto fh ispr o fes s i onal career wit h CelgeneCo r po ration, on e  of  t he larg est, gl obalb iopharm aceutical  companie s.  Hew a s C hairman of  Celgene  from Jan u ary 2 0 11  unti l J une 20 11 , E xecut ive Ch a irm an fr om Jun e2010 u ntilJa nuary 20 11 and Chairman and Chi ef Exe cutiv e O fficer fr omM ay2006 unti l Ju ne 2010. P rev iou sly,hew as ap poin t ed  Pr e siden t in 1993 andC hi efO p er ating Offic e r in1994bef o re ass umin g the CEO positio n . He also serv ed a s Sen ior Vice  P resident, Scie nce  a n d  Technol og y, and Vice  Preside nt / Gener al Man ager,ChiralP r od u cts, f romOct ober 1990  to  O c tober 1 99 3, and Vi ce P re sident , Tech n olog y ,  from September1987t o  Octo b er1990.  r . Barer serv es as Chai rman of the  Board  ofInspi reMD, I nc . (NYS E M KT : NSPR), a medical d evice  compan yfocu sin g on t he d e v elopm entan d c ommercial i z at i on  o f  aprop rieta ry  ste nt system technolo gy, and Res to rGe n e x Corp o ra t i on (OTCQB:  RE SX),a company in thef ie l d ofdermat ologyand can c er.  H e alsoser v e s as Chai rman of t h e B oa rd o f severa lpriv at e c om panies includin g Centre xion Cor p o ration , C e reco r , Inc. ,ContraF


In summary,_this document_presented mitigation identification techniques_for Cisco_NX-OS_ACLs, ACL_logging,_spoofing protection using_uRPF, and Cisco_NX-OS NetFlow. It explained_how to display_attempts_to bypass protections and exploit vulnerabilities. It is at the administrator's discretion to modify_the_show commands_used_in_this document for their own_specific needs to identify if_security policies_deployed to mitigate certain vulnerabilities or threats have_been_successful.

Additional Information

Risk Management

Organizations_are advised to follow their standard risk evaluation and_mitigation processes to determine the potential_impact of vulnerabilities._Triage_refers_to sorting projects and_prioritizing efforts that are most likely_to be successful. Cisco has provided_documents that can help organizations develop a_risk-based triage capability for their information_security teams. Risk Triage for_Security Vulnerability_Announcements and Risk Triage and_Prototyping can help_organizations develop_repeatable security evaluation_and response processes.

This document is provided_on an "as_is" basis and does not imply_any_kind of guarantee_or_warranty,_including the_warranties of merchantability_or_fitness for_a_particular use. Your use of the_information_on the document or materials linked from_the document is at_your_own risk. Cisco reserves_the right to change or_update this document at any time._Biographies

Dr. Sol_J. Barer,_Ph.D., is the Non-Executive Chairman of the Board of the company._He spent most of his professional_career with Celgene Corporation,_one of_the_largest, global biopharmaceutical_companies._He was_Chairman of Celgene from January 2011 until_June 2011,_Executive Chairman from June 2010 until_January 2011 and Chairman_and_Chief Executive Officer from May 2006_until June 2010. Previously, he was_appointed President in 1993 and_Chief_Operating_Officer in 1994 before assuming_the CEO position. He also served_as Senior Vice_President, Science and Technology, and Vice President/General_Manager,_Chiral Products, from October 1990 to_October_1993, and Vice President, Technology, from_September_1987_to October 1990. r. Barer_serves as Chairman of the Board_of InspireMD, Inc. (NYSE MKT: NSPR), a medical device_company focusing on_the development and commercialization of_a_proprietary_stent system technology, and RestorGenex Corporation (OTCQB: RESX), a company_in the_field of dermatology_and cancer. He also serves as Chairman of the Board_of several private companies including Centrexion Corporation,_Cerecor, Inc., ContraF